FY26 funding package blocked in Senate after ICE shooting of Alex Pretti New package—likely excluding DHS—may go back to House early next week

NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH

Budgets can surprise you, and the White House budget proposal for fiscal year 2027 is more surprising than most.

April 03, 2026

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).

March 27, 2026

Vol.52 No.12

By Sara Willa Ernst and Paul Goldberg

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

NCI

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.

Mass General Brigham receives $50M gift for gene and cell therapy research

Mass General Brigham has received a $50 million gift for gene and cell therapy research. The gift, made by anonymous donors, will advance clinical research by experts at Mass General Brigham Cancer Institute and throughout the system, to deliver treatments for patients with cancer and other diseases.

March 13, 2026

Vol.52 No.10

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti

New package—likely excluding DHS—may go back to House early next week

YOU MAY BE INTERESTED IN

NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Mass General Brigham receives $50M gift for gene and cell therapy research

Renew today!

Subscriber content

Never miss an issue!

Login

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti

New package—likely excluding DHS—may go back to House early next week

YOU MAY BE INTERESTED IN

NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Mass General Brigham receives $50M gift for gene and cell therapy research

Never miss an issue!

Login

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”